Neurofibromatosis type 1

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1471, Issue 1, 2000, Pages

  Parada, Luis F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Animal model; Knockout; Neurofibromatosis; p53; Tumor suppressor

Indexed keywords

NEUROFIBROMIN;

CLINICAL FEATURE; DISEASE ASSOCIATION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; NEUROFIBROMATOSIS; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; TUMOR MODEL;

ALLELES; ANIMALS; CELL LINE; DROSOPHILA; GENES, NEUROFIBROMATOSIS 1; GENES, P53; HUMANS; MICE; MODELS, ANIMAL; MUTATION; NEUROFIBROMATOSIS 1;

EID: 0034738419     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(00)00014-7     Document Type: Short Survey

References (50)

1. Hinds P.W., Weinberg R.A. Tumor suppressor genes. Curr. Opin. Genet. Dev. 4:1994;135-141.
2. Riccardi V.M., Womack J.E., Jacks T. Neurofibromatosis and related tumors. Natural occurrence and animal models. Am. J. Pathol. 145:1994;994-1000.
3. Ballester R., Marchuk D., Boguski M., Saulino A., Letcher R., Wigler M., Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 63:1990;851-859.
4. Buchberg A.M., Cleveland L.S., Jenkins N.A., Copeland N.G. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature. 347:1990;291-294.
5. Cawthon R.M., Weiss R., Xu G.F., Viskochil D., Culver M., Stevens J., Robertson M., Dunn D., Gesteland R., O'Connell P., et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 62:1990;193-201.
6. Xu G.F., Lin B., Tanaka K., Dunn D., Wood D., Gesteland R., White R., Weiss R., Tamanoi F. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 63:1990;835-841.
7. Xu G.F., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., White R., et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 62:1990;599-608.
8. Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 63:1990;843-849.
9. Legius E., Marchuk D.A., Collins F.S., Glover T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat. Genet. 3:1993;122-126.
10. Reynolds J.E., Fletcher J.A., Lytle C.H., Nie L., Morton C.C., Diehl S.R. Molecular characterization of a 17q11.2 translocation in a malignant schwannoma cell line. Hum. Genet. 90:1992;450-456.
11. Xu W., Mulligan L.M., Ponder M.A., Liu L., Smith B.A., Mathew C.G., Ponder B.A. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer. 4:1992;337-342.
12. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients (see comments). Nature. 356:1992;713-715.
13. Bollag G., Clapp D.W., Shih S., Adler F., Zhang Y.Y., Thompson P., Lange B.J., Freedman M.H., McCormick F., Jacks T., Shannon K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12:1996;144-148.
14. DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., Lowy D.R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 69:1992;265-273.
15. Guha A., Lau N., Huvar I., Gutmann D., Provias J., Pawson T., Boss G. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene. 12:1996;507-513.
16. Knudson A.G. Jr. Genetics of human cancer. Annu. Rev. Genet. 20:1986;231-251.
17. Weinberg R.A. The molecular basis of oncogenes and tumor suppressor genes. Ann. N.Y. Acad. Sci. 758:1995;331-338.
18. Attardi L.D., Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol. Life Sci. 55:1999;48-63.
19. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
20. Giovannini M., Robanus-Maandag E., Niwa-Kawakita M., van der Valk M., Woodruff J.M., Goutebroze L., Merel P., Berns A., Thomas G. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 13:1999;978-986.
21. Jacks T. Tumor suppressor gene mutations in mice. Annu. Rev. Genet. 30:1996;603-636.
22. McClatchey A.I., Saotome I., Mercer K., Crowley D., Gusella J.F., Bronson R.T., Jacks T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12:1998;1121-1133.
23. Rudolph K.L., Chang S., Lee H.W., Blasco M., Gottlieb G.J., Greider C., DePinho R.A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 96:1999;701-712.
24. Brannan C.I., Perkins A.S., Vogel K.S., Ratner N., Nordlund M.L., Reid S.W., Buchberg A.M., Jenkins N.A., Parada L.F., Copeland N.G. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues (published erratum appeared in Genes Dev. 8 (1994) 2792). Genes Dev. 8:1994;1019-1029.
25. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1994;1-7.
26. Jacks T., Shih T.S., Schmitt E.M., Bronson R.T., Bernards A., Weinberg R.A. Tumour predisposition in mice heterozygous for a targeted mutation in NF1. Nat. Genet. 7:1994;353-361.
27. Kim H.A., DeClue J.E., Ratner N. cAMP-dependent protein kinase A is required for Schwann cell growth: interactions between the cAMP and neuregulin/tyrosine kinase pathways. J. Neurosci. Res. 49:1997;236-247.
28. Kim H.A., Ling B., Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol. Cell Biol. 17:1997;862-872.
29. Kim H.A., Rosenbaum T., Marchionni M.A., Ratner N., DeClue J.E. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene. 11:1995;325-335.
30. Guo H.F., The I., Hannan F., Bernards A., Zhong Y. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science. 276:1997;795-798.
31. The I., Hannigan G.E., Cowley G.S., Reginald S., Zhong Y., Gusella J.F., Hariharan I.K., Bernards A. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science. 276:1997;791-794.
32. Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., Bronson R.T., Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science. 286:1999;2172-2176.
33. Tanaka M., Omura K., Watanabe Y., Oda Y., Nakanishi I. Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J. Surg. Oncol. 57:1994;57-64.
34. White R.L. Colon cancer. Molecular biology of the APC protein. Pathol. Biol. (Paris). 45:1997;240-244.
35. Zhu Y., Richardson J.A., Parada L.F., Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:1998;703-714.
36. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
37. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
38. Srivastava S., Zou Z.Q., Pirollo K., Blattner W., Chang E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome (see comments). Nature. 348:1990;747-749.
39. Gerosa P.L., Spinelli M., Iannarelli S., Giussani G., Canepari C., Fontana A., Vai C., Bizzozero L. Tumour suppressor genes, immunology and local manifestations of neurofibromatosis phenotypes. Panminerva Med. 38:1996;157-163.
40. Halling K.C., Scheithauer B.W., Halling A.C., Nascimento A.G., Ziesmer S.C., Roche P.C., Wollan P.C. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am. J. Clin. Pathol. 106:1996;282-288.
41. Luria D., Avigad S., Cohen I.J., Stark B., Weitz R., Zaizov R. p53 mutation as the second event in juvenile chronic myelogenous leukemia in a patient with neurofibromatosis type 1. Cancer. 80:1997;2013-2018.
42. Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science. 286:1999;2176-2179.
43. Klesse L.J., Meyers K.A., Marshall C.J., Parada L.F. Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene. 18:1999;2055-2068.
44. Klesse L.J., Parada L.F. p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. J. Neurosci. 18:1998;10420-10428.
45. Baubonis W., Sauer B. Genomic targeting with purified Cre recombinase. Nucleic Acids Res. 21:1993;2025-2029.
46. Betz U.A., Vosshenrich C.A., Rajewsky K., Muller W. Bypass of lethality with mosaic mice generated by Cre-loxP-mediated recombination. Curr. Biol. 6:1996;1307-1316.
47. Feil R., Brocard J., Mascrez B., LeMeur M., Metzger D., Chambon P. Ligand-activated site-specific recombination in mice. Proc. Natl. Acad. Sci. USA. 93:1996;10887-10890.
48. Vogel K.S., Brannan C.I., Jenkins N.A., Copeland N.G., Parada L.F. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell. 82:1995;733-742.
49. Vogel K.S., Parada L.F. Sympathetic neuron survival and proliferation are prolonged by loss of p53 and neurofibromin. Mol. Cell. Neurosci. 11:1998;19-28.
50. Kamijo T., Bodner S., van de Kamp E., Randle D.H., Sherr C.J. Cancer Res. 59:1999;2212-2217.